RxDoctor Payments Data

Karl Damiani, MD

Infectious Disease · Port Charlotte, FLNPI 1497743744

Payments from drug & device makers

$3,245in general payments, 2019–2025

Across 82 payments — averaging $39.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Paratek Pharmaceuticals, Inc.$546
  • Insmed, Inc.$463
  • Viiv Healthcare Company$271
  • Merck$198
  • Cook Medical LLC$103
  • plus $287 from 5 others

What the payments were for

  • Food & beverage$3,22699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$526,726
Medicare patients
643
Services billed
503,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala123$559,725
ArikayceAmikacin Liposomal/Neb.Accessr33$490,129
EpclusaSofosbuvir/Velpatasvir20$468,641
NuzyraOmadacycline Tosylate22$172,720
PrezcobixDarunavir/Cobicistat44$109,940
Daptomycin33$67,891
StribildElviteg/Cob/Emtri/Tenofo Disop12$47,109
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$43,491
TivicayDolutegravir Sodium19$42,305
IsentressRaltegravir Potassium13$30,103
EdurantRilpivirine Hcl20$28,749
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df43$24,699
DescovyEmtricitabine/Tenofov Alafenam11$24,225
Isentress HdRaltegravir Potassium12$23,575
Rifabutin32$19,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Epclusa, Stribild, Descovy$1,376$1,099,700166 claims
Insmed, Inc.Arikayce$463$490,12933 claims
Paratek Pharmaceuticals, Inc.Nuzyra$546$172,72022 claims
MerckIsentress, Isentress Hd$198$53,67825 claims
Viiv Healthcare CompanyTivicay$271$42,30519 claims
Smith+NephewSantyl$75$6,57816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →